Shandong Lukang Pharmaceutical (600789.SH) subsidiary obtained registration certificate for finasteride tablets.

Shandong Lukang Pharmaceutical (600789.SH) announced that its holding subsidiary, Shandong Lukang Pharmaceutical Group Sate Pharmaceutical Co., Ltd. (referred to as "Sate Company"), recently received the "Drug Registration Certificate" for finasteride tablets issued by the National Medical Products Administration (batch numbers: 2025S03900, 2025S03901). The drug is a generic drug that has been approved under the new registration classification 4, and is considered to have passed the consistency evaluation of generic drug quality and efficacy. Finasteride is a synthetic steroid compound that is a specific inhibitor of the intracellular enzyme type II 5-reductase in the process of testosterone metabolism into dihydrotestosterone (DHT), which is a male hormone. Benign prostatic hyperplasia (BPH), also known as prostate enlargement, depends on the conversion of testosterone to DHT in the prostate. This drug can effectively reduce the levels of DHT in the blood and prostate. The 1mg dosage is used to treat male pattern baldness, promote hair growth, and prevent further hair loss; the 5mg dosage is used to treat and control BPH, as well as prevent urinary system events. It can shrink the enlarged prostate, improve urine flow, and alleviate symptoms related to prostate enlargement.